Trials / Completed

CompletedNCT00037804

Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction

Status: Completed
Phase: Phase 1
Study type: Interventional
Enrollment: —

Sponsor: Pfizer · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

Drugs used in chemotherapy us different ways to stop tumor cells from dividing so they stop growing or die. Irinotecan may be effective in treating patients with refractory solid tumors and liver dysfunction.

Conditions

Unspecified Adult Solid Tumor
Chemotherapy
Liver Dysfunction
Neoplasms, Solid Tumor

Interventions

Type	Name	Description
DRUG	Irinotecan

Timeline

First posted: 2002-05-22
Last updated: 2009-08-14

Locations

4 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00037804. Inclusion in this directory is not an endorsement.